Successful treatment of relapses of primary mediastinal large B-cell lymphoma with central nervous system involvement
Open Access
- 16 November 2023
- journal article
- research article
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (3) , 398-409
Abstract
Introduction. Relapses of primary mediastinal large B-cell lymphoma (PMBСL) with involvement of the central nervous system (CNS) are usually incurable. Therapy tactics in patients with PMBCL with relapse in the CNS have not been defined. Aim: to present clinical observations of the treatment of relapses of PMBCL with CNS involvement using the “R-PML-CNS-2022” protocol. Main findings. Two clinical observations of patients with relapses of PMBCL with involvement of the CNS are presented. In both cases, the “R-PML—CNS-2022” protocol was used as a second-line treatment, and a complete remission of the disease was achieved. In the first case, within 6 months after auto-HCT, maintenance therapy with pembrolizumab was performed. Complete remission of the disease continues for 15 months. In the second observation, maintenance therapy with pembrolizumab was also started, however, due to the development of autoimmune complications after 2 cycles, treatment was discontinued. Complete remission of the disease continues for 13 months. Conclusion. The development of a new strategy for the treatment of relapses of PMLCL with CNS lesion according to the “R-PML—CNS-2022” protocol is a potentially curative approach in this group of patients.Keywords
This publication has 24 references indexed in Scilit:
- Maintenance lenalidomide in primary CNS lymphomaAnnals of Oncology, 2019
- Autologous Stem-Cell Transplantation for Primary Central Nervous System Lymphoma: Systematic Review and Meta-analysisClinical Lymphoma Myeloma and Leukemia, 2019
- Biology and therapy of primary mediastinal B‐cell lymphoma: current status and future directionsBritish Journal of Haematology, 2019
- Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.Journal of Clinical Oncology, 2018
- Nivolumab maintenance after salvage autologous stem cell transplantation results in long‐term remission in multiple relapsed primary CNS lymphomaEuropean Journal of Haematology, 2018
- CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOPJournal of Clinical Oncology, 2016
- R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphomaBlood, 2015
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- Early CNS relapse in a good-risk primary mediastinal large B-cell lymphoma after combined chemo- and radio-therapyJournal of Neuro-Oncology, 2010
- CNS recurrence of primary mediastinal large b-cell lymphoma after complete remissionJournal of Neuro-Oncology, 2009